Fox Chase Cancer Center News

PHILADELPHIA (May 26, 2021)—Although there have been treatment advances over the years, multiple myeloma is still an incurable disease. It is characterized by periods of remission and relapse resulting in decreased survival outcomes following initial therapies. But now, Fox Chase Cancer Center is one of a handful of hospitals in the country to offer patients a new treatment option.

PHILADELPHIA (May 24, 2021)—Mary B. Daly, MD, PhD, FACP, professor in the Department of Clinical Genetics and director of the Risk Assessment Program at Fox Chase Cancer Center, recently received the National Comprehensive Cancer Network’s (NCCN) Rodger Winn Award.

PHILADELPHIA (May 19, 2021)—In a study released today, researchers at Fox Chase Cancer Center and a team of international researchers identified a mutated gene called LRRK2 that may indicate a predisposition to malignant mesothelioma.  

PHILADELPHIA (May 18, 2021)—Data from a new study by researchers at Fox Chase Cancer show that avapritinib, a platelet-derived growth factor receptor A (PDGFRA) inhibitor, has a “clinically meaningful benefit” for the treatment of gastrointestinal stromal tumors (GIST) with PDGFRA D842V mutations.

PHILADELPHIA (May 18, 2021) – In a study posted today, researchers at Fox Chase Cancer Center announced that they have discovered a new factor contributing to early lung cancer formation.

PHILADELPHIA (May 14, 2021)—In early 2020, Sanjay S. Reddy, MD, FACS, surgical oncologist and co-director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center, co-authored an article examining the paradox that healthcare providers were facing. Should they continue to treat cancer patients as they normally would, which might increase the risk of contracting COVID-19? Or should they try alternative strategies to treatment, which could lead to worse cancer-related outcomes?

PHILADELPHIA (May 14, 2021)—In a recent study, researchers at Fox Chase Cancer Center found that there are major limitations in using cystoscopy for predicting the presence of muscle-invasive bladder cancer in patients who are candidates for bladder removal.

PHILADELPHIA (May 12, 2021)—In a recent study, researchers at Fox Chase Cancer Center showed that the combined use of the drugs venetoclax (Venclexta) and ibrutinib (Imbruvica) could help eradicate residual disease in patients with chronic lymphocytic leukemia (CLL).